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Abstract
Background This retrospective study was designed to
estimate the clinical remission (CR) rate of tonsillectomy
plus steroid pulse (TSP) therapy in patients with IgA
nephropathy.
Methods Based on 292 of 302 patients with IgA
nephropathy treated at 11 Japanese hospitals, we con-
structed heat maps of the CR rate at 1 year after TSP with
the estimated glomerular filtration rate (eGFR), grade of
hematuria, pathological grade, number of years from
diagnosis until TSP, and age at diagnosis on the vertical
axis and the daily amount of urinary protein (urinary pro-
tein) on the horizontal axis. We compared subgroups
usinge Student’s t test, the chi-square test with Yates cor-
rection, or Fisher’s exact probability test.
Results The first heat map of eGFR and urinary protein
showed that the CR rate was 71 % (CR vs. non-CR, 96 vs.
40) in patients with eGFR greater than 30 ml/min/1.73 m2
and 0.3–1.09 g/day of urinary protein. However, the CR
rate in patients with more than 1.50 g/day of urinary pro-
tein was approximately 30 %. The second heat map of
grade of hematuria and urinary protein revealed that the CR
rate is 72 % (CR vs. non-CR, 93 vs. 37) in patients with
more than 1? hematuria and 0.3–1.09 g/day of urinary
protein; however, it was 28.6 % in patients with no
hematuria. The third heat map of pathological grade and
urinary protein demonstrated that the highest CR rate was
83 % (CR vs. non-CR, 52 vs. 11) in patients with patho-
logical grade I or II disease and less than 1.09 g/day of
urinary protein, as opposed to 22 % (CR vs. non-CR, 9 vs.
32) in patients with pathological grade III or IV disease and
more than 2.0 g/day of urinary protein. The fourth heat
map of the number of years from diagnosis until TSP and
urinary protein revealed that the former did not influence
the CR rate in patients with less than 1.09 g/day of urinary
protein. However, in patients with more than 1.10 g/day of
urinary protein, the CR rate of the subgroup with less than
6 years was 43 % (CR vs. non-CR; 23 vs. 54) compared to
23 % (CR vs. non-CR, 11 vs. 48; P = 0.01) in the sub-
group with more than 6 years. The fifth heat map of age at
diagnosis and urinary protein showed that the CR rate is
approximately 72 % (CR vs. non-CR, 73 vs. 28) in patients
older than 19 years at diagnosis with 0.3–1.09 g/day of
urinary protein.
Conclusions The daily amount of urinary protein is an
important predictor of the CR rate after TSP in IgA
nephropathy patients. Heat maps are useful tools for pre-
dicting the CR rate associated with TSP.
Keywords Clinical remission  Heat map  IgA
nephropathy  Tonsillectomy plus steroid pulse
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Introduction
In 2001, Hotta et al. [1] proposed tonsillectomy plus steroid
pulse (TSP) as a new approach that can induce clinical
remission (CR) in IgA nephropathy patients. The profile of
329 patients in their retrospective study was as follows: age
K. Suzuki  N. Miura  H. Imai (&)
Division of Nephrology and Rheumatology, Department
of Internal Medicine, Aichi Medical University School







Clin Exp Nephrol (2014) 18:606–612
DOI 10.1007/s10157-013-0867-8
(mean ± SD), 36.1 ± 12.8 years; daily proteinuria,
1.40 ± 1.09 g; serum creatinine, 1.14 ± 0.48 mg/dl. In a
Cox regression analysis with 13 variables, serum creatinine
\1.3 mg/dl, daily proteinuria between 0.5 and 1.5 g, his-
tological score (index of glomerular lesion, calculated by
the degree of mesangial proliferation and sclerosis)\2.00,
steroid pulse therapy, and tonsillectomy were identified as
prognostic factors for CR. Recently, a subsequent analysis
revealed that each year 600 patients in Japan received TSP
in 2006 [2]. In 2010, more than 1,000 patients per year
received TSP in Japan, with half achieving CR, defined as
no urinary abnormalities, 1 year after treatment. In a ret-
rospective multicenter study, Miura et al. found that
54.1 % of patients reached CR at 1 year after TSP. There
were significant differences between patients who reached
CR and those who did not reach CR in terms of the number
of years from diagnosis until TSP (P = 0.02), daily pro-
teinuria (P \ 0.0001), serum creatinine (P = 0.006), and
pathological grade (P = 0.0006). Multivariate logistic
regression analysis demonstrated that factors associated
with resistance to TSP include young age, massive amounts
of urinary protein, absence of hematuria, and severe path-
ological grade. Our present study was designed to clarify
the indications and limitations of TSP for IgA nephropathy
patients and to clarify whether a heat map, by using several
factors on vertical axis and daily amount of urinary protein
on horizontal axis, can predict CR.
Methods
The present retrospective multicenter study was approved
by the Ethics Committee of Aichi Medical University and
was designed as a sub-analysis of previously reported data.
Patients
From our previous study involving 303 patients [2], 292
with sufficient laboratory data such as the daily amount of
urinary protein and serum creatinine values were analyzed
here. The present study included 128 males and 164
females, whose mean age was 34.17 ± 13.75 years
(range, 12–73). The mean duration from diagnosis to TSP
was 6.1 ± 6.1 years. The daily amount of urinary protein
was 1.10 ± 1.29 g, and the serum creatinine level was
0.93 ± 0.38 mg/dl. There were 14, 47, 74, and 157
patients with hematuria grade 0, 1?, 2?, and 3?,
respectively. The distribution of pathological grade was: I,
14 patients; II, 57 patients; III, 120 patients; IV, 101
patients. The prevalence of antihypertensive medication
use was 41.6 %. The CR rate at 1 year after TSP was
55.5 %. Previous studies using multivariate logistic
regression have identified several factors that predict
resistance to TSP such as age at diagnosis, daily amount
of urinary protein, hematuria, and pathological grade. The
use of angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers and gender had no impact
on CR in previous studies.
The definition of CR
CR was determined based on urinary analysis, as described
in a previous report [2]. Remission of proteinuria was
defined as negative (-) or trace (±) proteinuria on the
urine dipstick test, while remission of hematuria was
specified as the absence of blood on the dipstick test and
urinalysis. CR was defined as the complete resolution of
both proteinuria and hematuria.
Estimation of the glomerular filtration rate (GFR)
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Pathological grade
Pathological grade of the kidney biopsy was assessed by
pathologists or nephrologists at each participating hospital
during using the previous criteria from the Joint Committee
of the Research Group on Progressive Renal Diseases and
the Japanese Society of Nephrology [4].
Biopsy samples were graded based on the following
criteria:
Grade I: Glomerular findings: Slight mesangial cell
proliferation and increased matrix. Glomerulosclerosis,
crescent formation, or adhesion to Bowman’s capsule is not
observed. Interstitial and vascular findings: Prominent
changes are not seen in the interstitium, renal tubuli, or
blood vessels.
Grade II: Glomerular findings: Slight mesangial cell
proliferation and increased matrix. Glomerulosclerosis,
crescent formation, or adhesion to Bowman’s capsule seen
in\10 % of all biopsied glomeruli. Interstitial and vascular
findings: Prominent changes are not seen in the interstit-
ium, renal tubuli, or blood vessels.
Grade III: Glomerular findings: Moderate, diffuse mes-
angial cell proliferation and increased matrix. Glomerulo-
sclerosis crescent formation or adhesion to Bowman’s
capsule seen in 10–30 % of all biopsied glomeruli. Inter-
stitial and vascular findings: Cellular infiltration is slight in
the interstitium except around some sclerosed glomeruli.
Tubular atrophy is slight, and mild vascular sclerosis is
observed.
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Grade IV: Glomerular findings: Severe, diffuse cell
proliferation and increased matrix. Glomerulosclerosis,
crescent formation, or adhesion to Bowman’s capsule seen
in[30 % of all biopsied glomeruli. When sites of sclerosis
are totaled and converted to global sclerosis, the sclerosis
rate is [50 % of all glomeruli. Some glomeruli also show
compensatory hypertrophy. The sclerosis rate is the most
important of these indices. Interstitial and vascular find-
ings: Interstitial cellular infiltration and tubular atrophy, as
well as fibrosis are seen. Hyperplasia or degeneration may
be seen in some intrarenal arteriolar walls.
Construction of the CR rate heat maps
Clinical remission was shown as ‘‘C’’ and non-clinical
remission as ‘‘N.’’ The CR rate was calculated in each cell.
Cells were color coded by the CR rate with [66 % rep-
resented by dark blue, 50–65 % by light blue, 50 % by
yellow, 33–49 % by orange, \33 % by dark red, and
patient number zero by white.
The first heat map (Fig. 1) shows the CR rate according
to eGFR and urinary protein levels. eGFR, depicted on the
vertical axis, was divided into eight subgroups with eGFR
[90, 80–89, 70–79, 60–69, 50–59, 40–49, 30–39, and
15–29 ml/min/1.73 m2, respectively. Urinary protein was
divided into nine subgroups: \0.29, 0.30–0.49, 0.50–0.69,
0.70–0.89, 0.90–1.09, 1.10–1.49, 1.50–1.99, 2.00–2.99, and
[3.00 g/day. The second heat map (Fig. 2) has the grade
of hematuria on the vertical axis and urinary protein on the
horizontal axis. The third heat map (Fig. 3) has the path-
ological grade on the vertical axis and urinary protein on
the horizontal axis. A fourth heat map, with the number of
years from diagnosis until TSP on the vertical axis and
urinary protein on the horizontal axis, was also constructed
(Fig. 4). The number of years from diagnosis until TSP was
divided into five subgroups: \1.0, 1.0–2.99, 3.0–5.99,
6.0–8.99, 9.0–14.99, and[15.0 years, respectively. A fifth
heat map was constructed using age at diagnosis on the
vertical axis and urinary protein on the horizontal axis
(Fig. 5). Age at diagnosis was divided into six subgroups:
\19, 20–29, 30–39, 40–49, 50–59, and [60 years.
Statistical analysis
Quantitative values were expressed as mean ± SD,
unless otherwise noted. Data comparisons were carried
out using Student’s t test or the chi-square test with the
Yates correction for continuity or Fisher’s exact proba-
bility test. P values \0.05 were considered statistically
significant.
Fig. 1 A heat map of the CR rate based on the eGFR value and daily
amount of urinary protein. A gradation from dark blue in the upper
left corner to dark red in the lower right corner is observed. A
relatively high CR rate of 71 % (CR vs. non-CR, 96 vs. 40) was
observed in patients with eGFR greater than 30 ml/min/1.73 m2 and
0.3–1.09 g/day of urinary protein. On the other hand, the CR rate in
patients with more than 1.50 g/day of urinary protein was 29.6 % (CR
vs. non-CR, 21 vs. 50). The CR rate in patients with hematuria alone
(\0.29 g/day of urinary protein) was relatively low at 60.8 % (CR vs.
non-CR, 31 vs. 20), compared to 73 % (CR vs. non-CR, 60 vs. 22) in
patients with 0.3–0.69 g/day of urinary protein (P = 0.19). Patients
with \0.29 g/day of urinary protein and eGFR of 60–69 ml/min/
1.73 m2 have a low CR rate; however, there is no significant
difference among these subgroups
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Results
The CR rate according to eGFR and urinary protein
levels
Figure 1 shows a heat map of the CR rate at 1 year after
TSP for IgA nephropathy patients, which demonstrates a
gradient from high to low CR rates. There is a significant
difference between subgroups with less than 1.09 g/day of
proteinuria (CR vs. non-CR, 128 vs. 62) and more than
1.10 g/day (CR vs. non-CR, 34 vs. 68; P \ 0.00001). A
high CR rate of 71 % (CR vs. non-CR, 96 vs. 40) was
observed in patients with eGFR levels greater than 30 ml/
min/1.73 m2 and 0.3–1.09 g/day of urinary protein. On the
other hand, the CR rate in the subgroup with more than
1.50 g/day of urinary protein was 29.6 %. In contrast, the
CR rate was as low as 60.8 % in patients with hematuria
alone (\0.29 g/day of urinary protein; CR vs. non-CR, 31
vs. 20) compared to 73 % in patients with 0.3–0.69 g/day of
urinary protein (CR vs. non-CR, 60 vs. 22; P = 0.19).
Fig. 2 A heat map of the CR
rate based on the grade of
hematuria and daily amount of
urinary protein. A graduation
from dark blue in the upper left
corner to dark red in the lower
right corner is observed.
Patients with no hematuria had a
worse CR rate, 28.6 % (CR vs.
non-CR, 4 vs. 10), compared to
subgroups with hematuria
(56 %; CR vs. non-CR, 158 vs.
124; P = 0.04). The CR rate
was 72 % (CR vs. non-CR, 108
vs. 49) in patients with more
than 1? hematuria and
0.3–0.89 g/day of urinary
protein. The CR rate was
25.6 % (CR vs. non-CR, 11 vs.
32) in patients with more than
1? hematuria and more than
2.0 g/day of urinary protein
Fig. 3 A heat map of the CR
rate based on pathological grade
and daily amount of urinary
protein. A gradation from dark
blue in the upper left corner to
dark red in the lower right
corner is observed. The CR rate
of patients with pathological
grade I or II disease and
\1.09 g of daily urinary protein
was 82.5 % (CR vs. non-CR, 52
vs. 11). In contrast, the CR rate
of patients with pathological
grade III or IV disease and more
than 2.0 g of daily urinary
protein was 28.1 % (CR vs.
non-CR, 9 vs. 32; P \ 0.00001)
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Patients with\0.29 g/day of urinary protein and 60–69 ml/
min/1.73 m2 of eGFR had a low CR rate, but there was no
significant difference.
The CR rate according to the grade of hematuria
and urinary protein
Figure 2 shows that the CR rate was 72 % (CR vs. non-
CR, 108 vs. 49) in patients with more than 1? hematuria
and 0.3–0.89 g/day of urinary protein; however, the CR
rate was 28.6 % in patients without hematuria (14 out of
292 patients). The CR rate of the 1?, 2?, and 3?
hematuria subgroups was 59.6, 56.8, and 56.1 %,
respectively.
The CR rate according to pathological grade
and urinary protein
Figure 3 demonstrates that the CR rate in patients with
pathological grade I or II disease and \1.09 g/day of
Fig. 4 A heat map of the CR
rate based on the number of
years from diagnosis until TSP
and daily amount of urinary
protein. A gradation from dark
blue starting to the left of 1.09 g
of daily urinary protein to dark
red on the right is observed. In
patients with daily urinary
protein between 0.3 and 1.09 g,
the number of years from
diagnosis until TSP did not
influence the CR rate, which
was in the 70 % range.
However, in patients with more
than 1.10 g/day of urinary
protein, the CR rate of the
subgroup with less than 6 years
was 43 % (CR vs. non-CR, 23
vs. 54) compared to 23 % in the
subgroup with more than
6 years (CR vs. non-CR, 11 vs.
48; P = 0.01)
Fig. 5 A heat map of the CR
rate based on the age at
diagnosis and daily amount of
urinary protein. A graduation
from dark blue starting from the
lower left of 0.3–0.89 g of
urinary protein to dark red on
the right is observed. The CR
rate was 73 % (CR vs. non-CR,
88 vs. 35) in patients with
0.3–1.09 g/day of urinary
protein who were older than
20 years at diagnosis. However,
relatively low CR rates of 52.8
and 42.2 % were found in
patients \19 years old and
between 40 and 49 years old at
diagnosis, respectively
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urinary protein was 82.5 % (CR vs. non-CR, 52 vs. 11),
whereas the subgroup with pathological grade III or IV
disease and more than 2.0 g/day of urinary protein had a
CR rate of 28.1 % (CR vs. non-CR, 9 vs. 32; P \ 0.00001).
The former subgroup had the highest CR rate, while the
latter had the lowest CR rate.
The CR rate according to the number of years
from diagnosis until TSP and urinary protein
Figure 4 shows that the number of years from diagnosis until
TSP did not influence the CR rate in patients with between
0.3 and 1.09 g/day of urinary protein. The CR rate was
approximately 70 % in these subgroups. However, in
patients with more than 1.10 g/day of urinary protein, the CR
rate of the subgroup with less than 6 years was 43 % (CR vs.
non-CR, 23 vs. 54), compared to 23 % for the subgroup with
more than 6 years (CR vs. non-CR, 11 vs. 48; P = 0.01).
The CR rate according to the age at diagnosis
and urinary protein level
Figure 5 shows that the CR rate was 73 % (CR vs. non-CR;
88 vs. 35) in patients with between 0.3 and 1.09 g/day of
urinary protein who were more than 20 years old at diag-
nosis. However, relatively low CR rates of 52.8 and 42.2 %
were found in patients \19 years old and between 40 and
49 years old, respectively.
There was no relationship between the number of years
from diagnosis until TSP and pathological grade or eGFR,
respectively (data not shown).
Discussion
This study revealed three major points. The first is that heat
maps, based on eGFR and urinary protein, or pathological
grade and urinary protein, can predict the CR rate at 1 year
after TSP therapy in patients with IgA nephropathy. The
second is that urinary protein is an important factor influ-
encing the CR rate among the variables studied, which also
included grade of hematuria, pathological grade, number of
years from diagnosis until TSP, and age at diagnosis. The
third is that patients with proteinuria alone (without
hematuria) or hematuria alone (\0.29 g/day of urinary
protein) have relatively low CR rates of 28.5 and 60.8 %,
respectively.
Heat maps are useful tools for physicians to predict the
CR rate in individual patients and to explain the predicted
CR rate to patients and their families. The highest CR rate
was 82.5 % in patients with pathological grade I or II
disease and \1.09 g/day of urinary protein, and approxi-
mately 70 % in patients with eGFR [30 ml/min/1.73 m2
and \1.09 g/day of urinary protein. These subgroups are
good candidates for TSP. On the other hand, a poor CR rate
of approximately 30 % was observed in patients with more
than 1.5 g/day of urinary protein regardless of eGFR. A
randomized controlled trial comparing TSP, steroid pulse
therapy, and antiplatelet drugs is needed to clarify the best
treatment for IgA nephropathy patients with \1.09 g/day
of urinary protein, because observations on long-term
outcomes of IgA nephropathy with minimal or no pro-
teinuria have revealed that 37.5 % of patients reach CR
after a median of 48 months [5].
Recently, Ieiri et al. [6] emphasized that a shorter
duration from diagnosis until TSP is associated with a high
likelihood of CR in IgA nephropathy patients treated with
TSP. In our previous study, the comparison between
patients who reached CR and those who did not reach CR
revealed significant differences in the number of years
from diagnosis until TSP (P = 0.02), daily proteinuria
(P \ 0.0001), serum creatinine (P = 0.006), and patho-
logical grade (P = 0.0006). However, multivariate logistic
regression analysis did not identify the number of years
from diagnosis until TSP as a predictive factor. The present
study also revealed that the number of years from diagnosis
until TSP does not necessarily influence the CR rate; when
patients have between 0.3 and 1.09 g/day of urinary pro-
tein, the CR rate is approximately 70 %, independent of the
number of years from diagnosis until TSP. On the other
hand, the number of years form diagnosis until TSP is an
important factor in patients with more than 1.1 g/day of
urinary protein, because the CR rate was 23 % in patients
with more than 6 years from diagnosis until TSP compared
to 43 % in patients with\6 years from diagnosis until TSP
(P = 0.01). The above results suggest that urinary protein
is a more essential predictive factor than the number of
years from diagnosis until TSP.
Regarding resistance to TSP, based on multivariate
logistic regression analysis we previously reported that
resistance to TSP therapy depends on age at diagnosis,
urinary proteinuria, grade of hematuria, and pathological
grade [2]; namely, young age and the absence of hematuria
are associated with resistance to TSP. Recently, Ieiri et al.
[6] also pointed out that higher age has a favorable impact
on the CR rate after TSP. With regards to hematuria, the
present study demonstrated that the CR rate in patients with
no hematuria (14 out of 292 IgA nephropathy patients) is
only 28.6 % compared to 59.6, 56.8, and 56.1 % in patients
with 1?, 2?, and 3? hematuria, respectively. Extensive
review of the literature on the relationship between TSP
and hematuria revealed no studies except for our previous
report [2]. IgA nephropathy patients without hematuria
may have nephrosclerosis or hereditary nephritis with
concomitant glomerular IgA deposition, because 4 % of
normal persons without urinary abnormalities are reported
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to have glomerular IgA deposition on postmortem exami-
nation after accidental death [7]. Concomitant glomerular
IgA deposition has been reported in hereditary nephritis,
including thin basement membrane disease [8–10], mild
Alport syndrome [11], focal segmental glomerulosclerosis
[12], and complement factor abnormalities [13]. Moreover,
the CR rate in patients without proteinuria (mainly hema-
turia alone) is relatively low, 60.8 % compared to
approximately 73.0 % in patients with 0.3–0.69 g/day of
urinary protein. TSP hardly induces CR in these patients of
combination with hereditary nephritis and glomerular IgA
deposition. We have to pay attention to the diagnostic
criteria of IgA nephropathy when patients show no hema-
turia or no proteinuria because thin basement membrane
disease occurs in up to 9 % of the general population
according to an analysis of donor kidney grafts [14], and
concomitant glomerular IgA deposition is observed in 4 %
of normal population [7].
In conclusion, heat maps with the eGFR or pathological
grade and daily amount of urinary protein are useful tools
for predicting the CR rate of TSP for IgA nephropathy.
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